Viral hepatitis, characterised by inflammation of the liver and necrosis of hepatocytes, results from infection with viruses from several different families. The essentially hepatotropic viruses include a range of five different unrelated human pathogens: hepatitis A, B, C, D and E.
Viral hepatitis is a major public health problem. The World Health Organisation estimates that 1 in 12 of the human population has been infected with the hepatitis viruses. Over one‐third of the world population, some two billion people, have been infected with
hepatitis B virus
, and four million cases of acute hepatitis B occur every year. Reliable estimates for infection with hepatitis A, C, D and E are not available.
Hepatitis causes considerable morbidity and mortality, from both acute infection and chronic sequelae. It is estimated that there are over 350 million carriers of
hepatitis B virus
worldwide, and some 250 million carriers of
hepatitis C virus
.
Key Concepts:
Viral hepatitis remains a major public health problem with considerable morbidity and mortality.
Persistent infection may progress to chronic liver disease, cirrhosis and primary liver cancer.
Liver cancer is the seventh most common cancer in males and the ninth most common cancer in females.
Strategies for the prevention of viral hepatitis are still evolving, for example, effective vaccines and universal immunisation.
There is an urgent need to develop vaccines against infection with hepatitis C virus and hepatitis E virus infection in some developing regions of the world.
There is an urgent need to develop and apply new and more effective antiviral drugs.
The need to implement some basic public health measures to reduce the burden of infection with the hepatitis viruses, for example, social conditions and health education.
Paid blood donations, which are known to carry a high risk of transmissible viral infections, should be prohibited by law.
It is essential that national public health authorities ensure the safety of injections, as the estimated total burden of infection due to unsafe injection practices in developing countries (WHO study, 2000) is 21 million cases of hepatitis B; 2 million cases of hepatitis C and 260 000 cases of HIV infection.
Control of viral hepatitis will lead to a highly significant improvement of health in all countries.